Physician profile
Benigno Rodriguez
NPI 1043230691
$58,040.60
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $9,660.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $39,968.55 | 2019-2020 | |
| Gilead Sciences, INC. | $15,478.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $1,342.08 | 2019 | |
| Theratechnologies INC. | $914.04 | 2019 | |
| Janssen Biotech, INC. | $117.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $86.84 | 2019-2020 | |
| Insmed, INC. | $41.46 | 2019 | |
| Allergan, INC. | $40.98 | 2019 | |
| Melinta Therapeutics, LLC | $21.78 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $15.13 | 2020 | |
| Napo Pharmaceuticals INC | $13.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benigno Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.